January 18, 2023
Video
Erika P. Hamilton, MD, discusses the findings from a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.
January 09, 2023
Video
Erika P. Hamilton, MD, discusses the wide-ranging impacts of the introduction of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive breast cancer.
December 12, 2022
Video
Erika P. Hamilton, MD, discusses the next steps following the successful outcomes of the phase 3 DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.
November 19, 2022
Video
Erika P. Hamilton, MD, discusses the key safety and efficacy findings from the phase 3 DESTINY-Breast03 study.
November 15, 2022
Video
Erika P. Hamilton, MD, discusses the purpose of a safety follow-up analysis for the DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.
September 06, 2022
Video
Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.